Objectives-Chronic hypertension is the most critical risk factor for cardiovascular disease, heart failure, and stroke. Approach and Results-Here we show that wild-type mice infused with angiotensin II develop hypertension, cardiac hypertrophy, perivascular fibrosis, and endothelial dysfunction with enhanced stromal interaction molecule 1 (STIM1) expression in heart and vessels. All these pathologies were significantly blunted in mice lacking STIM1 specifically in smooth muscle (Stim1 SMC−/− ). Mechanistically, STIM1 upregulation during angiotensin II-induced hypertension was associated with enhanced endoplasmic reticulum stress, and smooth muscle STIM1 was required for endoplasmic reticulum stress-induced vascular dysfunction through transforming growth factor-β and nicotinamide adenine dinucleotide phosphate oxidase-dependent pathways. Accordingly, knockout mice for the endoplasmic reticulum stress proapoptotic transcriptional factor, CCAAT-enhancer-binding protein homologous protein (CHOP −/− ), were resistant to hypertension-induced cardiovascular pathologies. Wild-type mice infused with angiotensin II, but not Stim1 SMC−/− or CHOP −/− mice showed elevated vascular nicotinamide adenine dinucleotide phosphate oxidase activity and reduced phosphorylated endothelial nitric oxide synthase, cGMP, and nitrite levels. Conclusions-Thus, smooth muscle STIM1 plays a crucial role in the development of hypertension and associated cardiovascular pathologies and represents a promising target for cardiovascular therapy. (Arterioscler Thromb Vasc Key Words: cardiac hypertrophy ◼ endothelial nitric oxide synthase ◼ ER stress ◼ hypertension ◼ nicotinamide adenine dinucleotide phosphate ◼ stromal interaction molecule 1 ◼ vascular reactivity
H ypertension is a major risk factor for cardiovascular complications, including heart failure and stroke in animal models and patients. 1, 2 Vascular reactivity is of paramount importance in regulating local blood flow and ensuring constant tissue perfusion. We and others reported that hypertension impairs vascular function through reduced endothelial nitric oxide synthase (eNOS) activity and enhanced activation of molecular pathways of stress, including endoplasmic reticulum (ER) stress and oxidative stress. [3] [4] [5] [6] [7] It is well established that increased intracellular calcium (Ca 2+ ) concentration is a key second messenger involved in cardiovascular homeostasis in terms of flow-induced dilation and vascular smooth muscle cell (SMC) and cardiomyocyte contractility. [8] [9] [10] Adequate physiological functions of both endothelial cells and SMC require accurate intracellular Ca 2+ regulation. [11] [12] [13] In particular, the ubiquitous store-operated Ca 2+ entry (SOCE) pathway has been shown to regulate many cell functions. [14] [15] [16] [17] In vascular disease states, SOCE is functional in endothelial cells, vascular smooth muscle cells, and cardiomyocytes and plays an essential role in the regulation of proliferation, migration, hypertrophy, and apoptosis. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Stromal interaction molecule 1 (STIM1) is an ER Ca 2+ sensor, which plays a critical role in the activation of Orai1 channels at the plasma membrane that mediate SOCE. 15, 18, [26] [27] [28] [29] Physiologically, SOCE is activated on receptor-mediated depletion of inositol-1,4,5-trisphopshate (IP 3 )-sensitive ER Ca 2+ stores. SOCE contributes to intracellular Ca 2+ refilling of the ER and also provides Ca 2+ microdomains crucial for downstream signaling to the nucleus. 30 In smooth muscle, we showed that STIM1 proteins are also required for the activation of another channel contributed by heteromultimeric of Orai1 and Orai3, which is activated by store-independent means involving intracellular actions of the inflammatory lipid second messenger, leukotriene C 4 . [31] [32] [33] [34] Our recent studies determined that the deletion of STIM1 specifically in SMC of mice reduces vascular contractile response to sympathetic stimulation, with no effect on endotheliumdependent relaxation. 23 Others and we showed that increased STIM1 expression is critical for the development of vascular and cardiac remodeling in animal models. 24, [35] [36] [37] The STIM1 expression is also enhanced in vessels of hypertensive rats compared with normotensive rats and is associated with elevated spontaneous tone and force generation. 38 Collectively, these studies suggest that upregulation of smooth muscle STIM1 could play a crucial role in vascular dysfunction and cardiac hypertrophy during hypertension. Thus, in the present study, we sought to determine the role and mechanisms of smooth muscle STIM1 in hypertension and the associated vascular dysfunction and cardiac hypertrophy using various tissue-specific knockout mice strains.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
One of the most obvious observations from this in vivo study is the reduced body weight of Stim1 SMC−/− mice, which is in agreement with previous studies. 3, 39 Indeed, regardless of whether mice were infused with saline or with angiotensin II (Ang II), body weight was significantly reduced in Stim1 SMC−/− compared to wild-type (WT), Stim1 SMC−/+ , and CCAATenhancer-binding protein homologous protein (CHOP −/− ) mice ( Figure 1A ). Importantly, in the Ang II-infused mice, hypertension was significantly delayed in Stim1 SMC−/− and CHOP −/− compared with WT and Stim1 SMC−/+ mice ( Figure 1B ).
STIM1 and CHOP Deletion Inhibits Hypertension-Mediated Cardiac Hypertrophy and Fibrosis
Cardiac hypertrophy was increased in WT and Stim1 SMC−/+ mice subjected to Ang II infusion, whereas Stim1 SMC−/− and CHOP −/− mice infused with Ang II were protected against cardiac hypertrophy ( Figure 1C ). Histological examination using collagen-specific Sirius-red staining on heart slices clearly demonstrated that chronic Ang II infusion induces perivascular fibrosis in WT group but not in Stim1 SMC−/− and CHOP −/− group ( Figure 1D ). Similarly, Western blot analysis on heart tissues showed that total and phosphorylated Smad2/3, STIM1, and the ER stress markers BiP (immunoglobin binding protein), ATF6 (activating transcription factor 6), and CHOP protein expression were increased in the WT group infused with Ang II but not in Stim1 SMC−/− and CHOP −/− groups ( Figure 1E and 1F). We used reverse transcriptase polymerase chain reaction on heart tissue samples to demonstrate that upregulation of these proteins in the WT group infused with Ang II occur at the mRNA level ( Figure 1G-1J ). Immunohistochemistry on heart sections showed an increase in STIM1 both in WT and CHOP −/− groups infused with Ang II but not in hearts from Stim1 SMC−/− mice infused with Ang II ( Figure 1K ; Figure IXA in the online-only Data Supplement). However, CHOP protein levels were only increased in WT mice infused with Ang II ( Figure 1L ; Figure IXB in the online-only Data Supplement). Together, these data suggest that STIM1 is acting upstream of CHOP and ER stress.
Effect of STIM1 and CHOP Deletion on Vascular Reactivity in Hypertension
The constriction of mesenteric resistance artery (MRA) in response to phenylephrine was significantly reduced in STIM1 SMC−/− compared to WT, Stim1 SMC−/+ , and CHOP −/− mice (Figure 2A ). However, this reduction in contraction in Stim1 SMC−/− was not altered in Ang II-infused hypertensive mice ( Figure 2D ). The contraction to a thromboxaneA2 agonist (U-46619) was similar in all groups ( Figure 2B ). However, in hypertension, thromboxaneA2 receptor-induced contraction was enhanced but to a lesser extent in STIM1 SMC−/− and CHOP −/− groups infused with Ang II ( Figure 2E ). The endothelium-dependent relaxation of MRA was identical in all control saline-infused groups ( Figure 2C ). However, in mice infused with Ang II, the endothelium-dependent relaxation in response to acetylcholine was impaired in WT and STIM1 SMC−/+ groups ( Figure 2F ). Interestingly, the endothelium-dependent relaxation was only partially inhibited (≈50%) in Stim1 SMC−/− mice infused with Ang II and was comparable to control levels in CHOP −/− mice infused with Ang II ( Figure 2F ).
Western blots demonstrated a more pronounced reduction in eNOS phosphorylation in WT mice infused with Ang II compared with Stim1 SMC−/− mice infused with Ang II, with the CHOP −/− mice infused with Ang II showing normal levels of eNOS phosphorylation ( Figure 2G ). Similarly, the cGMP and nitrite/nitrate levels (markers for NO signaling) were less reduced in STIM1 SMC−/− mice infused with Ang II by comparison to WT mice infused with Ang II ( Figure 2H and 2I). However, CHOP −/− mice infused with Ang II had essentially normal levels of cGMP and nitrite/nitrate ( Figure 2H and 2I). Consistent with eNOS, cGMP, and nitrite/nitrate data mentioned above, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity ( Figure 2K ), p47phox expression ( Figure VA in the online-only Data Supplement), mRNA levels of ROS NADPH oxidase (NOX) isoforms (Nox2 and 4; Figure VI in the online-only Data Supplement), and 8-OHD (8-hydroxy-2'-deoxyguanosine; Figure VIIA in the onlineonly Data Supplement) were significantly elevated in WT mice infused with Ang II compared with STIM1 SMC−/− and CHOP −/− mice infused with Ang II, with NADPH oxidase activity in CHOP −/− mice infused with Ang II, showing levels comparable to those of control saline-infused mice ( Figure 2K ). Interestingly, we noticed that Nox2 mRNA expression level was significantly reduced after STIM1 deletion in SMC ( Figure VIB in the online-only Data Supplement).
The results obtained earlier with the MRA were confirmed in conductance arteries (thoracic aortas). Indeed, contractility in response to phenylephrine ( Figure IA and IB in the To confirm our data, we measured in heart, MRA, and aorta tissues the NADPH oxidase activity in the presence and absence of L-NAME (nitro-L-arginine methyl ester) and apocynin ( Figure VIII in the online-only Data Figure 1 . Stromal interaction molecule 1 (STIM1) and CCAAT-enhancer-binding protein homologous protein (CHOP) mediate hypertension-induced cardiac damage and fibrosis. Body weight (BW; A, n=6) and systolic blood pressure (SBP) measured by tail cuff machine (B, n=6) in wild-type (WT), heterozygous (Stim1 SMC−/+ ), and homozygous (Stim1 SMC−/− ) Stim1 knockout specifically in SMC and CHOP knockout (CHOP −/− ) mice infused with or without angiotensin II (Ang II). Cardiac hypertrophy determined by evaluating heart weight/tibia length ratios (C, n=6); cardiac fibrosis stained with the collagen-specific Sirius-red (D, n=3); Western blot and quantification showing phosphorylated and total SMAD 2/3, STIM1 (E, n=3), and endoplasmic reticulum (ER) stress markers (ATF6, BiP, and CHOP; F, n=3); mRNA levels of ER stress marker (ATF6, CHOP, and BiP; G-I, n=3) and STIM1 (J, n=3); and immunohistochemistry showing STIM1 (K, n=3) and CHOP (L, n=3) in heart from WT, Stim1 SMC−/− , and CHOP −/− mice infused with saline or Ang II. Two-way repeated measured ANOVA followed by Tukey's post hoc test were applied for A and B. One Supplement). Our data showed that the increased NADPH oxidase in the WT group infused with Ang II was significantly reduced after treatment with L-NAME and apocynin ( Figure VIII 
STIM1 and CHOP Deletion Inhibits Vascular ER Stress in Hypertension
Because STIM1 is an ER protein of major importance in the maintenance of ER Ca 2+ homeostasis, and because specific lack of STIM1 in SMC protects against disruption of vascular and cardiac function during hypertension, we reasoned that STIM1 upregulation that occurs in hypertension might be mediating negative cardiovascular effects through exacerbation of ER stress. Indeed, we found that the expression of ER stress marker proteins BiP and ATF6 were significantly enhanced in MRA from WT mice infused with Ang II compared with all other groups ( Figure 2J ). STIM1 protein expression in MRA was greatly augmented in WT mice infused with Ang II compared with control saline-infused mice ( Figure 2L ). STIM1 protein expression was also significantly increased in Stim1 SMC−/− mice and CHOP −/− mice infused with Ang II compared with control saline-infused mice, but this increase was less pronounced in these 2 groups of mice compared with WT mice infused with Ang II ( Figure 2L ). The increase in STIM1 expression observed in MRA from Stim1 SMC−/− mice most likely reflects contributions from endothelial cells and possibly adventitial fibroblasts. 23 We also demonstrated that changes in protein expression observed earlier occur at the mRNA levels. Indeed, all ER stress markers BiP, ATF6, and CHOP mRNA levels, as well as STIM1 mRNA levels, were increased after Ang II infusion, and these increases were significantly decreased in Stim1 SMC−/− and blunted in CHOP −/− mice infused with Ang II (Figure 2M-2P ).
Effect of STIM1 and CHOP Deletion on Vascular Transforming Growth Factor-β and Reactive Oxygen Species in Hypertension
ER stress is an important determinant in the initiation of oxidative stress and transforming growth factor-β (TGF-β) signaling. Our previous studies showed that induction of ER stress in mice causes endothelial dysfunction and inhibits vascular reactivity through TGF-β and reactive oxygen speciesdependent mechanisms. 3 Therefore, we sought to determine the contribution of oxidative stress and TGF-β signaling in mediating vascular dysfunction downstream of STIM1 and ER stress using WT, Stim1 SMC−/+ , Stim1 SMC−/− , and CHOP −/− mice. We incubated MRA ex vivo with the TGF-β inhibitor, SB431542, or the NADPH oxidase inhibitor, gp-91-stat. In the control groups of WT, Stim1 SMC−/− , Stim1 SMC−/+ , and CHOP −/− saline-infused mice, the inhibition of TGF-β and NADPH oxidase had no effect on the endothelium-dependent relaxation of MRA ( Figure 3A, 3C, 3E, and 3G ). Similar results were obtained when thoracic aortas were used instead of MRA ( Figure IIA , IIC, IIE, and IIG in the online-only Data Supplement). Interestingly, when mice were infused with Ang II, the NADPH oxidase inhibitor gp-91-stat improved endothelium-dependent relaxation of MRA from WT and Stim1 SMC−/+ mice ( Figure 3B and 3D) but had no effect in thoracic aorta ( Figure IIB and IID in the online-only Data Supplement). Reciprocally, the inhibition of TGF-β improved endothelium-dependent relaxation in thoracic aorta of WT and Stim1 SMC−/+ mice infused with Ang II ( Figure IIB and IID in the online-only Data Supplement) but had no effect in MRA ( Figure 3B and 3D ). Consistent with a role for SMC STIM1 in promoting vascular dysfunction through ER stress-dependent mechanisms, endothelium-dependent relaxation of MRA and thoracic aorta was only partially inhibited in homozygous Stim1 SMC−/− mice and was preserved in CHOP −/− mice infused with Ang II. Furthermore, in both Stim1 SMC−/− and CHOP −/− mice, the TGF-β inhibitor and the NADPH oxidase inhibitor were without effect ( Figure 3F and 3H ; Figure IIF and IIH in the online-only Data Supplement).
Relationship Between ER Stress and STIM1
To directly establish the relationship between ER stress and STIM1, we injected WT, Stim1 SMC−/+ , and Stim1 SMC−/− mice with the ER stress inducer tunicamycin followed by measurements of vascular reactivity after 2 weeks. Tunicamycin significantly reduced the body weight in WT and heterozygous Stim1 SMC−/+ mice but had a noticeably smaller effect on the body weight of homozygous Stim1 SMC−/− mice ( Figure 4A ); please note that as shown earlier, untreated Stim1 SMC−/− mice have reduced body weight compared with WT and Stim1 SMC−/+ mice. Tunicamycin treatment had marginal effects on blood pressure that was essentially normal in all groups of mice ( Figure 4B ). Interestingly, endothelium-dependent relaxation in both MRA ( Figure 4C ) and thoracic aorta ( Figure IIIA in the online-only Data Supplement) was significantly impaired in WT and heterozygous Stim1 SMC−/+ mice injected with tunicamycin, whereas it was protected by ≈50% in homozygous Stim1 SMC−/− mice infused with tunicamycin. Consistently, infusion with tunicamycin caused a more pronounced reduction in total levels of eNOS in MRA ( Figure 4D ) and thoracic aorta ( Figure IIIB in the online-only Data Supplement) from WT and heterozygous Stim1 SMC−/+ mice compared with homozygous Stim1 SMC−/− mice.
Ex vivo experiments using the NADPH oxidase and TGF-β inhibitors as described earlier were performed to determine the contributions of oxidative stress and TGF-β signaling during ER stress induction in WT, Stim1 SMC−/+ , and Stim1 SMC−/− mice. Consistent with the results from Figure 3 and Figure II in the online-only Data Supplement, the NADPH oxidase inhibitor gp-91-stat greatly improved endothelium-dependent relaxation of MRA from WT and Stim1 SMC−/+ mice treated with tunicamycin ( Figure 5A and 5B) , compared with the effect observed in thoracic aorta ( Figure IVA and IVB in the online-only Data Supplement). Reciprocally, the inhibition of TGF-β signaling greatly improved endothelium-dependent relaxation in thoracic aorta of WT and Stim1 SMC−/+ mice treated with tunicamycin compared with the effect in MRA ( Figure 5A and 5B ; Figure  IVA and IVB in the online-only Data Supplement). Consistent with results obtained with Ang II infusion, endotheliumdependent relaxation in MRA and aortas from homozygous Stim1 SMC−/− mice was only partially inhibited by tunicamycin treatment, and additional treatment with the NADPH oxidase inhibitor or the TGF-β inhibitor was with no effect ( Figure 5C ; Figure IVC in the online-only Data Supplement). The main finding in this study is summarized in Figure X 
Discussion
The present study illustrates a novel mechanism connecting STIM1 to ER stress in mediating cardiac hypertrophy and vascular dysfunction in hypertension. The role of STIM1 in controlling several physiological processes, such as endothelial and smooth muscle functions has been well establis hed. 32, 33, 36, 40, 41 Others and we have previously shown that STIM1 is a master regulator of cardiovascular function; STIM1 protein expression is upregulated in vascular smooth muscle during vascular remodeling that is associated with phenotypic switching of smooth muscle from contractile to proliferative phenotypes. 12, [40] [41] [42] [43] The prevention of STIM1 upregulation using in vivo delivery of siRNA into vessels of living rats inhibits vascular remodeling and neointimal hyperplasia. [35] [36] [37] Although STIM1 expression is increased in vessels from hypertensive rats, 38 the role of STIM1 in hypertension and associated cardiac and vascular dysfunction remained unknown. Our data demonstrate a significant upregulation of STIM1 expression in heart and arteries during hypertension-induced cardiac damage and vascular dysfunction. We used mice with targeted gene deletion of STIM1 specifically in smooth muscle and infused them with Ang II to demonstrate that lack of STIM1 in smooth muscle prevents hypertension and hypertension-induced cardiac hypertrophy and vascular dysfunction through abrogation of ER stress.
It is well established that hypertension in animals and patients triggers cardiac hypertrophy and cardiac fibrosis. 44, 45 We show that cardiac hypertrophy and fibrosis induced by Ang II were associated with enhanced STIM1 expression. Interestingly, STIM1 deletion in SMC reduced Ang II-induced cardiac hypertrophy and fibrosis, suggesting that STIM1 in SMC is an important contributor to the development of cardiac damage in hypertension. Our data are supported by studies from our group and others showing increased STIM1 expression in neointimal hyperplasia and cardiac hypertrophy. 24, [35] [36] [37] 46 Additionally, our data indicate that ER stress markers were increased in the heart from WT mice infused with Ang II, which is in agreement with previous publications. 3, 47 STIM1 is a key regulator of Ca 2+ homeostasis by supporting communications between the ER and plasma membrane. Therefore, STIM1 upregulation could lead to ER stress and either directly or indirectly dictates the development of cardiovascular complications under hypertensive conditions. Thus, we determined that ER stress markers were reduced in the heart from Stim1 SMC−/− and CHOP −/− mice infused with Ang II. Also, we observed that CHOP −/− mice infused with Ang II were protected against the development of hypertension, cardiac fibrosis, and hypertrophy. Our data showed that STIM1 expression was increased in the heart from CHOP −/− mice infused with Ang II, suggesting that STIM1 is upstream of the ER stress marker (CHOP), but likely they are part of a positive loop.
It is well established that hypertension is associated with impaired vascular reactivity in animal models and patients, 5, 48 but the mechanisms involved in vascular dysfunction during hypertension are not fully understood. Here we report that vasoconstriction in response to phenylephrine is significantly reduced in Stim1 SMC−/− compared to WT mice, consistent with previous studies. 23, 39 This effect was independent of hypertension because vasoconstriction in response to phenylephrine in Stim1 SMC−/− mice infused with Ang II is also reduced. The vasoconstriction in response to phenylephrine in CHOP −/− mice with or without Ang II was similar to that in WT mice. Under control conditions (ie, in the absence of Ang II infusion), the vasoconstriction in response to the thromboxaneA2 analog U46619 was identical in all groups. However, in mice infused with Ang II, the U46619-induced contraction was augmented in WT and heterozygous Stim1 SMC−/+ mice and to a lesser extent in Stim1 SMC−/− and CHOP −/− mice. The difference in the vasoconstriction response between phenylephrine and U46619 could be explained by the fact that thromboxa-neA2 receptor signaling is not coupled to STIM1, whereas α1-adrenoceptor signaling is.
Endothelium-dependent relaxation of arteries depends on the activation of eNOS and cGMP signaling. 49 The deletion of STIM1 and CHOP did not alter the endothelium-dependent relaxation when compared with WT. However, after infusion of Ang II, the endothelium-dependent relaxation and eNOS phosphorylation were impaired in WT and Stim1 SMC−/+ mice but protected in Stim1 SMC−/− and CHOP −/− mice infused with Ang II. These data indicate that in hypertension, enhanced smooth muscle STIM1 and ER stress impair vascular endothelium-dependent relaxation. Several experimental and clinical evidence have linked the enhanced production of reactive oxygen species to hypertension. 50, 51 We showed an increase in NADPH oxidase activity in mice infused with Ang II, and this increase was blunted in Stim1 SMC−/− and CHOP −/− mice infused with Ang II. We previously reported that TGF-β, an important cytokine produced by smooth muscle, plays a major role in the impairment of endothelium-dependent relaxation in conductance arteries, whereas NADPH oxidase signaling is involved in resistance arteries. 3 Consistent with our previous studies, we found that in WT mice infused with Ang II, the inhibition of NADPH oxidase improves endothelium-dependent relaxation in resistance arteries, whereas TGF-β inhibition improves endothelium-dependent relaxation in the thoracic aorta. Interestingly, in Stim1 SMC−/− mice infused with Ang II, the inhibition of NADPH oxidase and TGF-β pathway did not improve further the endotheliumdependent relaxation, suggesting that STIM1 and NADPH oxidase/TGF-β pathways are not additive and likely mediating their effects through the same pathway. To determine the relationship between STIM1 and ER stress independently of hypertension, we treated mice with the ER stress inducer, tunicamycin. In agreement with our previous studies, 3, 4 tunicamycin did not enhance arterial blood pressure while impairing vascular endothelium-dependent relaxation in WT and heterozygous Stim1 SMC−/+ mice. However, in homozygous Stim1 SMC−/− mice, endothelium-dependent relaxation was protected after injection of tunicamycin. These results suggest a circular effect between STIM1 and ER stress. Future molecular studies are needed to determine the interaction between STIM1 and ER stress and the interplay: how STIM1 regulates ER stress and how ER stress regulates STIM1.
The mechanism by which SMC-specific deletion of STIM1 protects the endothelium-dependent relaxation in hypertension is still unknown. It is likely that SMC STIM1 regulates factors released by SMC that interact with endothelial cells and, therefore, eNOS activity. Future studies are needed to determine the link between SMC STIM1 and the endothelium-dependent relaxation.
The important implication from these data is that direct induction of ER stress independently of hypertension impairs vascular endothelium-dependent relaxation, and specific deletion of STIM1 in smooth muscle overcomes ER stressinduced vascular dysfunction. Our study provides new insights into the in vivo contribution and molecular mechanisms of smooth muscle STIM1 in hypertension-induced cardiac damage and vascular dysfunction. Therefore, specific targeting of smooth muscle STIM1 has the potential to overcome hypertension-induced cardiovascular complications.
Limitations
Previous studies by Giachini et al showed that normotensive and spontaneously hypertensive female rats have reduced store-operated Ca 2+ entry compared with normotensive and hypertensive males, respectively, and that was because of reduced expression of Orai1 and STIM1 in females. 52 The same authors showed that when spontaneously hypertensive females were ovariectomized, aortas from these female rats showed increased contraction and enhanced Orai1 expression, with no changes in STIM1 expression, suggesting that female sex hormones may downregulate Orai1-mediated Ca 2+ entry, thus, contributing to vascular protection in females. In fact, studies by Flourakis et al showed that the expression of Orai1 in prostate cancer is controlled by androgen, 53 whereas our previous studies showed that estrogen regulates the expression of the Orai3 isoform in breast cancer. 54, 55 Taken together, these data suggest that potentially a smaller ratio of Orai1 to Orai3 in females compared with males might contribute to vascular protection observed in females. Because STIM1 regulates the function of all 3 Orai isoforms, it is likely that our current findings have major relevance to both females and males. Clearly, additional studies comparing males and females side by side, similar to those of Giachini et al, 52 would be required to conclusively address this issue.
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